Economic Aspects in the Management of Diabetic Macular Edema in Italy

BackgroundDiabetic Macular Edema (DME) is the most common cause of vision loss in diabetic patients. Currently, the Vascular Endothelial Growth Factor inhibitors (anti-VEGFs) are used as the first line of DME treatment and corticosteroid implants are usually used as a second-line treatment. These im...

Full description

Bibliographic Details
Published in:Frontiers in Public Health
Main Authors: Giovanna Elisa Calabrò, Michele Basile, Monica Varano, Filippo Amore, Roberto Ricciardi, Francesco Bandello, Americo Cicchetti
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Subjects:
diabetic macular edema
economic burden
intravitreal dexamethasone implant
direct costs
indirect costs
Online Access:https://www.frontiersin.org/articles/10.3389/fpubh.2022.938987/full

Internet

https://www.frontiersin.org/articles/10.3389/fpubh.2022.938987/full

Similar Items